FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Bumetanide Injection, USP
Status: Currently in Shortage
»Date first posted: 12/13/2017
»Therapeutic Categories: Cardiovascular

Expand all

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 10/10/2019)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
0.25 mg/mL, 4 mL vial (NDC 0641-6008-10) Inventory is currently available. Additional lots are scheduled to be manufactured in the October - November 2019 timeframe. Product will be made available as it is released. Demand increase for the drug
0.25 mg/mL, 10 mL vial (NDC 0641-6007-10) Inventory is currently available. Additional lots are scheduled to be manufactured in the October - November 2019 timeframe. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc. (Revised 11/08/2019)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
1 mg/4 mL (0.25 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1412-04) Next Delivery: December 2019; Estimated Recovery: January 2020 Shortage per Manufacturer: Manufacturing Delay Other
2.5 mg/10 mL (0.25 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 00409-1412-10) Next Delivery: December 2019; Estimated Recovery: November 2020 Shortage per Manufacturer: Manufacturing Delay Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English